Indications for Germline Testing after Genomic Tumor Testing (CME/CNE)
Self-paced • 0.5 credits
About this course
The goal of genomic tumor testing is to identify biomarkers that have predictive (therapeutic) or prognostic significance for an active cancer. Some of the DNA variants detected through these tests that are relevant for therapeutic decisions can also be associated with hereditary cancer risks (e.g., BRCA1, BRCA2). Knowing when a hereditary variant is present can be helpful in identifying targeted treatments, informing about future cancer risks, and identifying when close relatives might be at risk. This module will help you interpret genomic tumor test results to determine when a patient should be further evaluated for hereditary (germline) risk. This module uses practice cases to facilitate learning-by-doing, discussion of in-depth topics, and additional resources for more detail.
Upon completion of this educational activity, the learner will be able to:
- Determine when germline testing may be indicated
- Recognize steps and resources to facilitate germline testing
Oncologists and other cancer clinicians, including fellows, physician assistants and nurses.
All information in Precision Oncology Online Education is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Oncology Online Education. Reliance on any information in Precision Oncology Online Education is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Oncology Online Education.